Evolution of frontline treatment of diffuse large B-cell lymphoma: a brief review and recent update

Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates o...

Descripción completa

Detalles Bibliográficos
Autores principales: Hong, Jung Yong, Suh, Cheolwon, Kim, Won Seog
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000Research 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4979644/
https://www.ncbi.nlm.nih.gov/pubmed/27606052
http://dx.doi.org/10.12688/f1000research.8790.1
Descripción
Sumario:Various strategies have been implemented to improve the outcomes of diffuse large B-cell lymphoma (DLBCL). In recent years, remarkable advances have been achieved, based on the discovery of cell-of-origin in DLBCL and on more effective targeted agents. This commentary will summarize recent updates on the evolution of frontline therapies for DLBCL, focusing on the upcoming promising frontline chemotherapy platforms and on activated B-cell subtype DLBCL and double-hit DLBCL.

Ejemplares similares